Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SASS-002
- Development stage
- Preclinical
- Lead developer
- Shionogi
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SASS-002 is an investigational small molecule carbonic anhydrase inhibitor being developed by Shionogi Apnimed Sleep Science (SASS), a joint venture between Shionogi and Apnimed. The drug is specifically designed for the treatment of obstructive sleep apnea (OSA). Carbonic anhydrase inhibitors are thought to treat sleep apnea by stabilizing respiratory control and reducing loop gain, which helps prevent the repetitive collapses of the airway during sleep. SASS-002 represents a pharmacological approach to OSA, a condition traditionally managed with mechanical interventions such as continuous positive airway pressure (CPAP) devices.
- Brand names
- Ospolot
- Other names
- sultiame
02
Targets
CA (Carbonic anhydrase)
Beyond the preview
Go deeper on SASS-002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SASS-002.